Literature DB >> 10508445

Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4.

G J Bridger1, R T Skerlj, S Padmanabhan, S A Martellucci, G W Henson, S Struyf, M Witvrouw, D Schols, E De Clercq.   

Abstract

Bis-tetraazamacrocycles such as the bicyclam AMD3100 are a class of potent and selective anti-HIV-1 and HIV-2 agents that inhibit virus replication by binding to the chemokine receptor CXCR4, the co-receptor for entry of X4 viruses. With the aim of optimizing the anti-HIV-1 and HIV-2 activity of bis-azamacrocycles, a series of analogues were synthesized which contain neutral heteroatom (oxygen, sulfur) or heteroaromatic (of lower pK(a) than a secondary amine) replacements for the amino groups of AMD3100. The introduction of one or more heteroatoms such as oxygen or sulfur into the macrocyclic ring of p-phenylenebis(methylene)-linked dimers (to give N(3)X or N(2)X(2) bis-macrocycles) gave analogues with substantially reduced anti-HIV-1 (III(B)) and anti-HIV-2 (ROD) potency. In addition, the bis-sulfur analogue was also markedly more cytotoxic to MT-4 cells. However, bis-tetraazamacrocycles featuring a single pyridine group incorporated within the macrocyclic framework exhibited anti-HIV-1 and HIV-2 potency comparable to that of their saturated, aliphatic counterparts. The p-phenylenebis(methylene)-linked dimer of the py[14]aneN(4) macrocycle inhibited HIV-1 replication at a 50% effective concentration (EC(50)) of 0.5 microM while remaining nontoxic to MT-4 cells at concentrations approaching 200 microM. A series of analogues containing macrocyclic heteroaromatic groups of varying pK(a) were also synthesized, and their ability to inhibit HIV replication was evaluated. Replacing the pyridine moiety of the py[14]aneN(4) macrocyclic ring with pyrazine or pyridine groups substituted in the 4-position (with electron-withdrawing or -donating groups) either reduced antiviral potency or increased cytotoxicity to MT-4 cells. Finally, we synthesized a series of analogues in which the ring size of the bis-pyridyl macrocycles was varied between 12 and 16 members per ring including the py[iso-14]aneN(4) ring system, an isomer of the py[14]aneN(4) macrocycle. The p-phenylenebis(methylene)-linked dimer of the py[iso-14]aneN(4) (AMD3329) displayed the highest antiviral activity of the bis-azamacrocyclic analogues reported to date, exhibiting EC(50)'s against the cytopathic effects of HIV-1 and HIV-2 replication of 0.8 and 1.6 nM, respectively, that is, about 3-5-fold lower than the EC(50) of AMD3100. AMD3329 also inhibited the binding of a specific CXCR4 mAb and the Ca(2+) flux induced by SDF-1alpha, the natural ligand for CXCR4, more potently than AMD3100. Furthermore, AMD3329 also interfered with virus-induced syncytium formation at an EC(50) of 12 nM.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10508445     DOI: 10.1021/jm990211i

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  15 in total

1.  Ligand-guided optimization of CXCR4 homology models for virtual screening using a multiple chemotype approach.

Authors:  Marco A C Neves; Sérgio Simões; M Luisa Sá e Melo
Journal:  J Comput Aided Mol Des       Date:  2010-10-20       Impact factor: 3.686

2.  Suppression of dualtropic human immunodeficiency virus type 1 by the CXCR4 antagonist AMD3100 is associated with efficiency of CXCR4 use and baseline virus composition.

Authors:  Signe Fransen; Gary Bridger; Jeannette M Whitcomb; Jonathan Toma; Eric Stawiski; Neil Parkin; Christos J Petropoulos; Wei Huang
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

Review 3.  Physiology and pharmacology of plerixafor.

Authors:  Simon P Fricker
Journal:  Transfus Med Hemother       Date:  2013-07-19       Impact factor: 3.747

4.  The pan-chemokine inhibitor NR58-3.14.3 abolishes tumour necrosis factor-alpha accumulation and leucocyte recruitment induced by lipopolysaccharide in vivo.

Authors:  J Reckless; L M Tatalick; D J Grainger
Journal:  Immunology       Date:  2001-06       Impact factor: 7.397

5.  First- and second-row transition metal oxa-aza macrocyclic complexes: a DFT study of an octahedral conformation.

Authors:  Francisco C A Lima; Rommel B Viana; Thais T da Silva; Solange M S V Wardell; Armando P Nascimento do Filho; José Walkimar M Carneiro; Moacyr Comar; Albérico B F da Silva
Journal:  J Mol Model       Date:  2012-01-15       Impact factor: 1.810

6.  Positron emission tomography imaging of tumors expressing the human chemokine receptor CXCR4 in mice with the use of 64Cu-AMD3100.

Authors:  Ido D Weiss; Orit Jacobson; Dale O Kiesewetter; John P Jacobus; Lawrence P Szajek; Xiaoyuan Chen; Joshua M Farber
Journal:  Mol Imaging Biol       Date:  2012-02       Impact factor: 3.488

7.  64Cu-AMD3100--a novel imaging agent for targeting chemokine receptor CXCR4.

Authors:  Orit Jacobson; Ido D Weiss; Lawrence Szajek; Joshua M Farber; Dale O Kiesewetter
Journal:  Bioorg Med Chem       Date:  2009-01-15       Impact factor: 3.641

8.  In vivo CXCR4 expression, lymphoid cell phenotype, and feline immunodeficiency virus infection.

Authors:  Sean P Troth; Alan D Dean; Edward A Hoover
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

9.  Impact of cytokines on replication in the thymus of primary human immunodeficiency virus type 1 isolates from infants.

Authors:  Livia Pedroza-Martins; W John Boscardin; Deborah J Anisman-Posner; Dominique Schols; Yvonne J Bryson; Christel H Uittenbogaart
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

10.  Discovery of novel aminopiperidinyl amide CXCR4 modulators through virtual screening and rational drug design.

Authors:  Yoon Hyeun Oum; Steven A Kell; Younghyoun Yoon; Zhongxing Liang; Pieter Burger; Hyunsuk Shim
Journal:  Eur J Med Chem       Date:  2020-06-06       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.